Compositions of morselized umbilical cord and/or amniotic membrane and methods of use thereof
Inventors
Tseng, Scheffer • Chua, Lorraine
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-9808491-B2
Publication Date
2017-11-07
Expiration Date
Abstract
The invention relates generally to the fields of biology and life sciences. More particularly, the invention relates to compositions and methods for modulating cellular physiology and pathological processing using a combination of compounds that can be found in morselized amniotic membrane tissue and morselized umbilical cord tissue preparations.
Core Innovation
The invention is directed to methods for treating an ocular wound or repairing damaged ocular tissue in an individual in need thereof by administering or applying a therapeutically effective gel composition comprising morselized placental amniotic membrane and morselized umbilical cord, together with a pharmaceutically-acceptable excipient. The morselized placental amniotic membrane and the morselized umbilical cord have a particle size of between about 0.1 mm to about 1.0 cm in length, width, and thickness, and are provided as a gel composition for ocular use.
The invention also includes applying an apparatus comprising an inert support and a gel composition comprising morselized placental amniotic membrane, morselized umbilical cord, or a combination thereof, for treating an ocular wound or repairing damaged ocular tissue. The apparatus approach disperses the gel composition on an inert support, including embodiments where the inert support is a mesh sheet with defined pore size.
Compositions are described as made from morselized human umbilical cord (Wharton’s jelly) and morselized amniotic membrane/stroma/jelly, with optional inclusion of placenta components/chorion, and can be provided in preservation and formulation forms including wet, dehydrated, and lyophilized compositions, as well as preserved and sterilized compositions. The disclosed compositions are stated to modulate cellular and tissue physiology, including suppressing TGFβ signaling, affecting macrophages and vascular endothelial cells (proliferation/migration/apoptosis), reducing fibroblast viability/inflammation, and protecting ocular epithelial/keratocyte cells.
Claims Coverage
The provided independent claims cover two core approaches: (i) administering a therapeutically effective gel composition containing morselized placental amniotic membrane and morselized umbilical cord, and (ii) applying an apparatus with an inert support carrying the same gel composition. Across the independent claim families, the main inventive features include specified particle size and ocular treatment/repair.
Ocular gel composition with defined particle size
Administering to the individual a therapeutically effective amount of a gel composition comprising a therapeutically effective amount of i) morselized placental amniotic membrane and ii) morselized umbilical cord; and a pharmaceutically-acceptable excipient, wherein the morselized placental amniotic membrane and the morselized umbilical cord have a particle size of between about 0.1 mm to about 1.0 cm in length, width, and thickness.
Ocular apparatus with inert support carrying defined particle size gel composition
Applying to the individual an apparatus comprising (a) an inert support, and (b) a gel composition comprising morselized placental amniotic membrane, morselized umbilical cord, or a combination thereof, wherein the morselized placental amniotic membrane and the morselized umbilical cord have a particle size of between about 0.1 mm to about 1.0 cm in length, width, and thickness.
Overall, the claim coverage focuses on ocular wound treatment or repair using a gel composition derived from morselized placental amniotic membrane and morselized umbilical cord with particle size dimensions in a defined range, either by direct administration or by application as part of an apparatus with an inert support.
Stated Advantages
Suppressing TGFβ signaling.
Affecting macrophages and vascular endothelial cells, including proliferation, migration, and apoptosis.
Reducing fibroblast viability and inflammation.
Protecting ocular epithelial and keratocyte cells.
Promoting wound healing.
Documented Applications
Treating an ocular wound.
Repairing damaged ocular tissue.
Ocular wounds and repairs using the disclosed compositions.
Interested in licensing this patent?